PER

1.37%

7.2¢ percheron therapeutics limited

@mac9 you talk a lot of sense. I believe the success of the CR...

First 65 Last

Share
Profile

Follow
chookman78

63 Posts.

29

14/07/23

20:53

Post #: 68798283
Share

Originally posted by mac9: ↑

At the previous CR history shows they did actually get a good price @24
There are many that are loud about the last CRs success, or lack of, but if you remember back then, and prior to it there was a lot of lobbying from retail for retail not to miss out and to be involved and dont just let the insto's have the opportunity.
With management getting hounded by the HC board members so much i think the retail offering was mainly provided to appease the loud shareholders.
And then retail let down the CR, if it had have been fully taken up by the retail arm then the CR would have been totally successful, and at a terrific price, right on the eve of a downturn in the whole Biotech sector internationally.
With retail doing their bit, how good would that have been.
So, there are a lot of complaints about the last CR but you know some blame can be laid at our feet for demanding involvement to which in the end we didnt commit adequately.
Maybe sometimes we are best served by being less demanding.

Re Directors buying shares, this has been discussed, but we all realise whether a Director buys shares or not is irrelevant to the success of the company?
I also like to see Directors buying up, because it instills confidance, but i also like seeing the Market buying up and Insto's buying up, it all instills confidance and in regard to the market and instos it can move the shareprice.
But this expectation that a Director should buy shares is unfair.
There are a multitude of reasons why a person may not buy shares, just look at your own situation, but it can be as simple as some people dont participate in the share market.
So it's an interesting sign when some do, but to expect Directors to buy shares because they are a Director is just unrealistic.

This CR is just another step in our progression forward and the next 12 months looks quite interesting for all us long and short term holders/owners.
We are in a new phase and the company has intentionally transitioned to suit that phase with new staff and final steps to testing our product for commercialisation, and if all goes well and there is a successful outcome, the value of ANP can then be determined by the market available by the return on goods sold minus the cost of goods sold, and that figure will not be small.
If we are successful.
Good luck and be patient.

Expand

@mac9 you talk a lot of sense.
I believe the success of the CR will depend on who they offer it to and what else they bring to the party. Hopefully more than just money & i dont think CG just wants to raise money. My hope is thats it's a strategic alliance.

ANP Price at posting: 6.5¢ Sentiment: Buy Disclosure: Held
13 Upvote

1 Great analysis

Reply

There are more pages in this discussion • 94 more messages in this thread...

First 65 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.2¢		Change -0.001(1.37%)		Mkt cap ! $64.91M

Open	High	Low	Value	Volume
7.4¢	7.5¢	7.2¢	$66.67K	916.5K

Buyers (Bids)

No.	Vol.	Price($)
3	127509	7.2¢

Sellers (Offers)

Price($)	Vol.	No.
7.4¢	97444	1

View Market Depth

No.	Vol.	Price($)
3	127509	0.072
2	33998	0.071
3	380000	0.070
2	232850	0.068
1	1510	0.066

Price($)	Vol.	No.
0.074	97444	1
0.077	120000	1
0.078	78800	1
0.080	102781	2
0.081	526316	2

Last trade - 15.23pm 24/05/2024 (20 minute delay)


Last 7.2¢		Change -0.001 ( 2.70 %)
Open	High	Low	Volume
7.3¢	7.3¢	7.2¢	1650
Last updated 13.54pm 24/05/2024 ?

PER (ASX) Chart

@mac9 you talk a lot of sense. I believe the success of the CR...

Featured News

Week 21 Wrap: NVIDIA's profits are up 600% – but this time, the market didn't really care

The Telstra twist - What the job cuts decision mean for investors?

Market Update: Energy the sole green sector as dull US mood sours Friday down under

Yandal lines up prime gold targets at Ironstone Well-Barwidgee

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Althea on a high as it opens cannabis drinks in the US with Flora Growth

Nimy seeks massive sulphide systems through surveying at WA prospects

Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW

AIC Mines raises $57m to extend Eloise copper mine lifecycle

PlaySide to take gamers back to Westeros with new PC title

Buyers (Bids)

Sellers (Offers)

Featured News

@mac9 you talk a lot of sense. I believe the success of the CR...

Featured News

Top Stories

Week 21 Wrap: NVIDIA's profits are up 600% – but this time, the market didn't really care

The Telstra twist - What the job cuts decision mean for investors?

Market Update: Energy the sole green sector as dull US mood sours Friday down under

Yandal lines up prime gold targets at Ironstone Well-Barwidgee

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Althea on a high as it opens cannabis drinks in the US with Flora Growth

Nimy seeks massive sulphide systems through surveying at WA prospects

Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW

AIC Mines raises $57m to extend Eloise copper mine lifecycle

PlaySide to take gamers back to Westeros with new PC title

Buyers (Bids)

Sellers (Offers)

Featured News